NeuroMetrix, Inc. is a commercial-stage neurotechnology company based in Woburn, Massachusetts. The Company is engaged in designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The Company has two principal product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. The Company’s DPNCheck is its testing technology for peripheral neuropathies. The Company’s Quell is its wearable neuromodulation technology for chronic pain. It refined approximately 200,000 chronic pain patients. Patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|May 3, 2023||Q1 Earnings Announcement||--||--||--|
|February 23, 2023||Q4 Earnings Announcement||--||--||--|
|October 20, 2022||Q3 Earnings Announcement||--||--||--|
|July 21, 2022||Q2 Earnings Announcement||--||--||--|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.